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Nerve growth factor (NGF) was the first-discovered member of the neurotrophin family,
a class of bioactive molecules which exerts powerful biological effects on the CNS
and other peripheral tissues, not only during development, but also during adulthood.
While these molecules have long been regarded as potential drugs to combat acute
and chronic neurodegenerative processes, as evidenced by the extensive data on
their neuroprotective properties, their clinical application has been hindered by their
unexpected side effects, as well as by difficulties in defining appropriate dosing
and administration strategies. This paper reviews aspects related to the endogenous
production of NGF in healthy and pathological conditions, along with conventional and
biomaterial-assisted delivery strategies, in an attempt to clarify the impediments to the
clinical application of this powerful molecule.
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INTRODUCTION
Since its discovery in the 1950s (Levi-Montalcini, 1987) and the award of the Nobel Prize
to Rita Levi-Montalcini and Stanley Cohen for their discoveries of growth factors in 1986,
the number of basic science discoveries and preclinical studies supporting the use of nerve
growth factor (NGF) for therapeutic purposes has constantly increased over the years, principally
for neurodegenerative diseases (Alzheimer’s disease, AD; and Parkinson’s disease, PD) and
brain injuries (perinatal hypoxia/ischemia, traumatic brain, and spinal cord injury), but also
retinopathies, optic nerve degeneration, and peripheral neuropathies associated with diabetes and
HIV. The potential applications have also extended from the nervous system as the primary target
to an increasing number of tissues and organs, including epithelial tissue, parenchymal organs, and
the osteoarticular system (Manni et al., 2013; Rocco et al., 2018), as well as inflammation (Skaper,
2017) and cancer (Griffin et al., 2018).
The road toward the clinical translation of NGF, however, has encountered numerous obstacles.
In spite of the success of Genentech in translating NGF production from male mouse salivary gland
extract (Bocchini and Angeletti, 1969) to the recombinant technology of the human form (Altar
et al., 1991; Rogers, 1996), results from early clinical trials led Genentech to terminate the rhNGF
(recombinant human NGF) project. This was based on side effects observed in two sets of phase
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II clinical trials, suggesting that despite the efficacy of rhNGF
administration at ameliorating the symptoms associated with
both diabetic polyneuropathy and HIV-related neuropathy, side
effects were dose limiting for NGF (Apfel, 2002). Moreover, a
large-scale phase III clinical trial of 1019 patients randomized
to receive either rhNGF or placebo for 48 weeks failed to
confirm these earlier indications of efficacy (Apfel, 2002).
Intravenous (IV), subcutaneous (SC), and intradermal (ID) NGF
injection induces myalgia, mechanic and thermal hyperalgesia,
emerging rapidly after injection and lasting for weeks (Mizumura
and Murase, 2015). As concerns human studies, SC or
intracerebroventricular (ICV) administration of rhNGF to
healthy subjects or patients with diabetic polyneuropathy, HIV-
associated peripheral neuropathy (SC, 0.03–1 µg/kg), AD (ICV,
75 µg/day for 3 months), PD (ICV, 3.3 mg infused over 23 days)
or hypoxic-ischemic perinatal brain injury (0.1 mg/day for
10 days) (reviewed by Tria et al., 1994; Mizumura and Murase,
2015) always produced hyperalgesia at the injection site, and in
some cases also mild to moderate-severe transient muscle pain
(Petty et al., 1994; Rogers, 1996) (clinical trial NCT00000842).
Actually, the current evidence regarding the painful side
effects of NGF administration is taking pharmacological research
in two new directions: development of humanized anti-
NGF monoclonal antibodies (anti-NGF mAbs) for conditions
as osteoarthritis, lower back pain, and interstitial cystitis
(Wise et al., 2021), and synthesis of TrkA ligands in an
attempt to overcome this severe and limiting side effect
(Carleton et al., 2018; Bagal et al., 2019). The rhNGF has
finally received FDA approval as Cenegermin R© eye drops
by Dompé, first-in-class with the potential to completely
heal rare neurotrophic keratitis (clinical trials NCT04293549,
NCT03836859, NCT02101281, NCT03019627).
However, the major obstacles to clinical translation of NGF
are also due to other factors, such as the biodistribution of this
large molecule, including its crossing of blood-tissue barriers, and
to issues of dosage, since NGF is produced by many different
cell types (Gostynska et al., 2020), and because endogenous NGF
production is altered in many of the pathologies included in a
tentative list of potential targets for the NGF drug.
This review addresses some of these major issues affecting the
development of innovative NGF delivery solutions, discussing
possible reasons for their success, and in many cases their
failures. Sections “Parenteral Administration” and “Topical
Application” refer to both preclinical and clinical studies, these
latter also indicated by the respective clinicaltrials.gov code;
section “Biomaterial-Assisted Delivery” refers to in vitro and
preclinical studies.
PARENTERAL ADMINISTRATION
NGF Endogenous Levels, Biodistribution
and Metabolism
In the body, NGF is produced according to a delicate balance
that varies from tissue to tissue also according to specific diseases
and pathological states (Lorenzini et al., 2021), and that can be
reflected by NGF blood levels
There is little data available on the biodistribution of
exogenously administered NGF. In the initial human applications
and clinical trials, mouse NGF or recombinant human NGF
(rhNGF) was SC (Petty et al., 1994; Rogers, 1996; Apfel
et al., 1998, 2000; McArthur et al., 2000; Schifitto et al., 2001)
(clinical trial NCT00000842) or ICV administered (Olson et al.,
1992; Jönhagen et al., 1998; Chiaretti et al., 2005, 2008), but
basic information on absorption, distribution and excretion
following parenteral administration derives from animal studies,
in particular in adult rats and in cynomolgus monkeys. In
this few biodistribution studies, mouse NGF was administrated
intravenously (IV) and SC in rats as a single injection (35 µg/kg,
single dose) or by continuous infusion via osmotic mini-pump
(50–450 µg/pump) (Tria et al., 1994). In monkeys, rhNGF
was administered SC (2 mg/kg), and pharmacokinetic analysis
was conducted after single and multiple doses (for 15 days,
every other day) (Nguyen et al., 2000). In both studies, the
maximum plasma concentrations (Cmax) confirmed that the drug
is absorbed after SC administration. In rats, the maximum blood
concentration of NGF after SC administration was 65-fold lower
than after IV injection. The calculated time to reach maximum
plasma concentrations (Tmax) are very similar in two studies,
despite the different doses employed. Multiple dosing in monkeys
shifts the Tmax from a mean value of 2.5 to 3.3 h (Nguyen et al.,
2000; Tria et al., 1994).
Subcutaneous administration via osmotic mini-pump
(450 µg/pump, corresponding to 37.5 µg/day) in rats resulted
in detectable NGF plasma levels after 6 h, reaching peak values
during day 1, confirming the Tmax delay after multiple dosing
(Tria et al., 1994). IV injection allows calculation of the half-life
distribution phase (t1/2α ), reached in 5–6 min, indicating a rapid
disappearance from plasma, probably due to the binding of NGF
to the α2-macroglobulin cleared from blood by hepatocytes (Tria
et al., 1994). With regard to NGF metabolism, no degradation
products were observed in plasma after immunoprecipitation
and SDS-PAGE, suggesting a long-term stability of the protein
(Tria et al., 1994; Nguyen et al., 2000). Table 1 summarizes
the basic pharmacokinetic parameters following comparable
administration routes.
Data regarding tissue distribution were obtained following the
administration of radiolabeled rhNGF (125I-rhNGF) in primates
(multiple dosing, for 15 days, every other day). The large central
volume of distribution (V2/F, 827 ml/kg) indicated distribution
TABLE 1 | Main PK parameters evaluated in animal studies, following comparable
single subcutaneous injection (data from Tria et al., 1994; Nguyen et al., 2000).
Monkeys Rats
rhNGF mNGF
Dose 2 mg/kg 35 µg/kg
Cmax (ng/ml) 1300 ± 120 3.57 ± 0.33
Tmax (h) 2.5 ± 2.7 3.20 ± 0.49
t1/2β (h) 4.1 ± 1.0 4.47 ± 0.15
Cmax , maximum plasma concentration; Tmax , time to reach maximum plasma
concentration; t1/2β , elimination phase half-life.
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in extravascular tissues. The organs were then collected at 8
and 24 h following dose 1 and dose 15. In non-neuronal tissues
125I-rhNGF was detected at both time points and doses in all
studied tissues, particularly in the thyroid, adrenals, kidneys, liver,
spleen, peripheral and axillary tissues, and at the injection site. As
expected, the radiolabeled drug was observed in the peripheral
nervous system, whereas it was minimal in the spinal cord, and
absent in the brain (Nguyen et al., 2000).
The plasma elimination half-life (t1/2β) is very close both
in rats and in monkeys (Table 1) and can be extended by
varying the administration route, e.g., 4.47 h in SC versus 2.30 h
in IV injection in rats. The administration schedule does not
appear to affect this parameter, e.g., 4.1 h versus 4.8 h following
single and multiple dosing. The clearance values (Cl) are not
affected by administration route, e.g., 6.38 ml/min/kg in SC
versus 6.93 ml/min/kg in IV injection in rats, but decrease
following multiple administration, e.g., 140 ml/kg/hr versus
63 ml/kg/hr following single and multiple (Tria et al., 1994;
Nguyen et al., 2000).
With regard to NGF metabolism, analysis of radiolabeled
NGF in monkeys shows that urinary excretion represents the
main route of elimination, although traces of radioactivity were
found in the feces. No difference in elimination pattern was
observed between 24 and 120 h following single and multiple
dosing (Tria et al., 1994; Nguyen et al., 2000). There is also
very little data available on specific NGF metabolic products,
derived from immunoprecipitation and SDS-PAGE in monkey
tissue lysates. In non-neuronal tissues, low molecular mass bands
were observed in the kidney, liver and spleen, indicating that
intensive metabolism occurs in these organs. SDS-PAGE from
lysate of sympathetic ganglia and dorsal root ganglia also show
intense NGF metabolism, while material present in the peripheral
nerves (radial, sciatic, and tibial) was mostly negative (Tria et al.,
1994; Nguyen et al., 2000).
NGF and the Blood Brain Barrier
Peripheral administration of NGF to target the CNS is limited
by the poor ability of this molecule to cross the blood-brain
barrier (BBB), and by peripheral enzymatic degradation. The
unique properties of the BBB stem from CNS capillary histology,
where endothelial cells are held together by tight junctions which
limit the paracellular flux of solutes, and the presence of specific
transporters which regulate the passage of molecules to the
CNSs. Endothelial cells are covered by mural cells (pericytes
and smooth muscle cells) which contribute to the dynamics of
BBB control, and the microvascular tube is also surrounded
by the inner vascular and the outer parenchymal basement
membrane, providing an anchor for many signaling processes
and an additional barrier for cells and molecules accessing the
CNS. The blood vessels also interact with different immune
cells, mainly perivascular macrophages, and microglial cells,
representing the first line of innate immunity. Lastly, the direct
bridge from the microvessel to the neurons is the astrocyte,
a glial cell with extending processes which completely envelop
the vascular tube, connecting the microvessels to the neurons
(Daneman and Prat, 2015).
While the restrictive nature of the BBB allows for proper
neuronal function and protection of the neural tissue, and
maintains CNS homeostasis, it also constitutes an obstacle for
drug delivery. Whether NGF can penetrate the BBB and be
absorbed by the brain tissue, and under what conditions, is still
controversial, but the poor permeability of NGF through the
BBB under physiological conditions has been widely described
(Pan et al., 1998). However, the BBB is not a fixed structure,
undergoing pathophysiological adaptations which are not yet
fully understood. Although BBB formation starts during the
embryonic stage, soon after vessel formation in the developing
CNS (E11, in rats), the system continues to mature following
birth, increasing the strength of the paracellular barrier and
expression of the efflux transporter (Blanchette and Daneman,
2015), while pathological conditions, particularly inflammation,
are known to modify its structure and dynamics. In general,
different diseases (e.g., stroke, multiple sclerosis, epilepsy) are
characterized by the internalization and down-regulation of tight
junctions, increased rates of transcytosis, increased expression
of adhesion molecules for leukocytes leading to increased
leukocyte extravasation, degradation of the basal membrane,
and reduced microvessel coverage by pericytes and astrocytes
(Profaci et al., 2020). Specific pathologies may therefore offer time
window opportunities for exploiting altered BBB permeability
and increasing NGF transportation to the CNS.
Strategies to overcome the BBB for the CNS delivery of large
molecules as NGF represent a major goal, driving alternative
routes of administration [see section “Intranasal (IN)” and “Eye
Drops”] and pharmaceutical technologies as nanocarrier (see
section “Nanomedicines for NGF Delivery”).
TOPICAL APPLICATION
Intranasal (IN)
Due to its large surface area, the high degree of vascularization,
and the “nose-to-brain” pathways, the nasal cavity is an
interesting portal for systemic delivery and to by-pass the BBB.
The advantages of nose-to-brain drug delivery include safety
and avoidance of the hepatic first pass metabolism, as well as
its non-invasive nature and high patient compliance (Colombo
et al., 2011). Limitations include the possible dosing volume
through the nasal cavity and the consequent total amount of
drug delivered systemically or into the brain (Dong, 2018), active
mucociliary clearance of the mucosa, short retention time for
drug absorption, low permeability for hydrophilic drugs, and low
central nervous system (CNS) delivery for proteins (Erdõ et al.,
2018). For these reasons, many strategies are currently being
tested to enhance drug transport and distribution through the
“nose-to-brain” pathways.
To give a brief anatomical overview, the nasal cavity consists
of three anatomical areas, the nasal vestibule, respiratory region,
and olfactory region, each characterized by different mucosal
epithelia. Figure 1 shows the cell composition of the olfactory
part of nasal cavity, mucosa, olfactory epithelium and lamina
propria, including the detail of the NGF, TrkA, and p75NTR
expression on different cell types.
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FIGURE 1 | NGF and olfactory system. (A) Sagittal view of the head with highlighted the area occupied by the nasal cavity. (B) Magnification of the nasal cavity with,
in the square, the area occupied by the olfactory epithelium. (C) Cell composition of the olfactory part of the nasal cavity, mucosa, olfactory epithelium, and lamina
propria. The olfactory epithelium is surrounded by layer globose and horizontal basal cells. It consists in many cellular types: sustentacular cells, Bowman’s glands
producing mucus, immature olfactory neurons and mature olfactory sensory neurons that project their axons toward the olfactory bulb through the cribriform plate.
Axons are enclosed by olfactory ensheating cells and olfactory nerve fibroblasts. The picture includes data on the expression of NGF, TrkA and p75NTR in the
different cellular populations of the olfactory epithelium (from Feron et al., 2008).
The respiratory epithelium is a ciliated pseudostratified
columnar epithelium composed by four main cell types – ciliated
and non-ciliated columnar cells, basal or horizontal cells and
goblet cells – with high vascularization, supplied by the arterial
branch of the maxillary artery. A mucus gel layer covers the
epithelium, that, together with ciliary tip movements, constitutes
the first protective barrier against inhaled particulates and
irritants. The respiratory mucus layer is renewed every 10–20 min
(Pardeshi and Belgamwar, 2013).
While the respiratory region is mainly involved in systemic
drug absorption, the olfactory area is important not only for the
ability of its neurons to provide the sense of smell, but also for
the “nose-to-brain path,” which delivers drugs directly into the
brain. The olfactory mucosa consists of a ciliated chemosensory
pseudostratified columnar epithelium that contains three types
of cells – olfactory sensory neurons, immature olfactory sensory
neurons and supporting (or sustentacular) cells – all connected
by tight junctions (Figures 1A,B). The cilia are non-motile, and
the overlying mucus gel has a very slow turnover (several days).
The olfactory mucosa presents the main inter-species
anatomical differences, an aspect which must be considered when
translating animal data to humans. In humans, this mucosa
covers 10% of the total surface area, while in rodents, the most
widely used species for intranasal administration studies, it can
constitute up to 50% of the total area. This is an important aspect,
because results obtained from animal models do not always
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correlate with those of humans, a discrepancy which probably
comes from an insufficient consideration of the anatomical and
physiological differences between the respective nasal cavities
(Cho et al., 2010). Rodents are more widely used for preliminary
nose-to-brain drug absorption studies, while rabbits and dogs are
used for pharmacokinetic studies.
Drugs transferred from the olfactory mucosa to the CNS
bypassing the BBB follow two pathways, olfactory and trigeminal,
with molecular transfer taking place outside or within the nerve
axon. The olfactory path includes the neuronal cells of the
olfactory epithelium, and the lamina propria and the olfactory
bulb in the CNS. The olfactory bulb then projects to the
cortex, amygdala and hypothalamus, providing an anatomical
link between nasal administration and the brain structures (Khan
et al., 2017). The trigeminal path consists of the trigeminal
nerve with its three major branches, ophthalmic, maxillary, and
mandibular, thus promoting the entrance of drugs to the caudal
and rostral parts of the brain. The olfactory path delivers drugs to
the rostral areas of the brain only, whereas the trigeminal pathway
delivers to both the rostral and caudal areas.
Following drug administration into the nasal cavity, the
first step of absorption is the passage through the mucus
layer and ciliary movement. After crossing this barrier, several
mechanisms are involved in the transmucosal transfer, such as the
paracellular pathway (the passive transport of molecules between
cells), or the transcellular pathway (active transport of the drug
across the cells). Carrier-mediated transport, transcytosis, and
transport through the intercellular tight junctions are other
possible pathways.
The entry of a wide range of molecules into olfactory sensory
neurons via an intracellular mechanism such as pinocytosis
or receptor-mediated endocytosis was first demonstrated for
BDNF (Deckner et al., 1993), and more recently for other
drugs such as ribavirin, an antiviral drug potentially useful
for the treatment of viral infections in both humans and
animals (Colombo et al., 2011; Giuliani et al., 2018). This
is the mechanism used by many viruses such as poliovirus
or herpesvirus, as well as by the latest example, the SARS-
CoV-2 virus. Following internalization in olfactory neurons,
the molecules (or viruses) run down the soma via retrograde
axonal transport. Neuronal transport is considered a slow
process. For example, intranasal delivery of 70 µg radiolabeled
BDNF, CNTF, NT-4, or erythropoietin (EPO) resulted in 0.1–
1.0 nM neurotrophin concentrations within 25 min in brain
parenchyma (Alcalá-Barraza et al., 2010). Intranasal studies
using labeled IGF-1 suggest that the rapid distribution toward
the CNS (∼30 min) is due to extracellular convection or
intracellular transport rather than to diffusion (Thorne et al.,
2004). Other studies report 45 min for the axonal transport phase
(Crowe et al., 2018).
Despite the presence of tight junctions (TJs), the use of
intercellular spaces has been hypothesized. These spaces are
generated by channels through which proteins, peptides (such
as insulin, IGF-1, albumin) and even stem cells can reach the
CNS, as demonstrated in the nasal mucosa, and by a transient
loosening of the BBB by decreasing expression of TJ proteins such
as claudin-1, occludin, and tricellulin (Jackson et al., 2017).
Although interest in this delivery route for preclinical
and clinical studies is increasing, very few studies of NGF
pharmacokinetics or biodistribution are available. In a study
on the Sprague Dawley rat hippocampus, for example, the
bioavailability of intranasally administered NGF with or without
chitosan was ∼14 fold greater than the group treated with NGF
without chitosan (Vaka et al., 2009). In a preclinical model of AD,
polymeric nanoparticles appear to be promising carriers for the
nose-to-brain delivery of drugs (Rabiee et al., 2021). Following
IN administration, rhNGF reached the brain within an hour,
achieving a concentration of 3400 pM in the olfactory bulb, 660–
2200 pM in other brain regions and, 240 and 180 pM in the
hippocampus and the amygdala, respectively, while, little or no
rhNGF was found in the brain following IV administration (Chen
et al., 1998). The therapeutic efficacy of IN NGF administration
has also been evaluated in many other brain diseases, and in
clinical trials of traumatic brain injury, acute ischemic stroke
and frontotemporal dementia (Eftimiadi et al., 2021). Notably,
no systemic or local side-effects have been described in clinical
trials using IN NGF administration in both adult (10 µl of NGF
at 200 µg/ml concentration, daily, for a 1-year period) (de Bellis
et al., 2018) and pediatric patients (0.1 mg/kg, three times daily
for 7 consecutive days) (Chiaretti et al., 2020).
Eye Drops
The eye is regarded as one of the main therapeutic targets
for NGF topical treatments. Local application of NGF exerts
a healing action on corneal and cutaneous ulcers associated
with pathological conditions such as inflammation, diabetes and
rheumatoid arthritis (Aloe et al., 2008), and the use of NGF as a
drug in ophthalmology is the best characterized and developed
clinical use of this neurotrophin (Eftimiadi et al., 2021). Since the
initial discovery that goldfish retinal cells are receptive to NGF
action (Turner and Delaney, 1979), many studies have shown
the potential therapeutic use of NGF to treat ophthalmic diseases
(Aloe et al., 2012), leading to a number of pre-clinical research
studies and clinical trials on different eye-related pathologies
(Aloe et al., 2012; Manni et al., 2013).
The most recent research into NGF treatments has focused
on neurotrophic keratitis, dry eye disease, optic neuropathy
and optic pathway glioma (Eftimiadi et al., 2021), and the
treatment of corneal ulcers of different etiologies, treated by
topical NGF application in more than 200 patients, is of major
interest (Lambiase et al., 2012). However, it was only in 2018,
following 30 years of clinical trials (Bonini et al., 2018), that
research finally led to the approval of a rhNGF produced in
bacteria, named Cenegermin (OxervateTM; Dompè Farmaceutici
SpA, Milan, Italy) for the treatment of neurotrophic keratitis. The
topical administration of NGF leads to complete corneal healing
(Bonini et al., 2018; Deeks and Lamb, 2020; Pflugfelder et al.,
2020), without inducing the development of pain and circulating
anti-NGF antibodies (Lambiase et al., 2007a).
But the retinal cells in the eye are part of the CNS and
constitutes the visual system together with the brain areas
receiving retinal input. The retina, which is part of the posterior
segment, is composed of different layers of nerve cell bodies
organized in nuclear and synaptic layers, transforming light into
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nerve signals. From the retina, the retinal ganglion cell (RGCs)
axons form the nerve fibers which converge in the optic disk and
form the optic nerve.
Thanks to this neural connection to the brain, the topical
application of NGF on eye is also regarded as a delivery route to
the brain. In fact, and in addition to innervating primary visual
areas, RGCs also extend their projections to the hypothalamus
and direct/indirect projections to different limbic structures
including the hippocampus and the septum (Tirassa et al., 2018;
Murcia-Belmonte and Erskine, 2019; Eftimiadi et al., 2021).
Figure 2 shows the structures of the visual system and in
particular of the eye (Figures 2A,B), including the detail of the
cell composition of the retina and the expression of NGF, TrkA
and p75NTR in the different cell populations (Figure 2C).
Although the eye has a number of anatomical and
physiological barriers which limit the absorption and transport
of molecules, topical application is nevertheless highly appealing.
Although bioavailability and efficacy after this route are lower
than a number of injection routes in different eye compartments
(intravitreal, subconjunctival, and retrobulbar), different drugs
are still capable of reaching the posterior segment of the eye.
Topical application also reduces the chance of systemic side
effects, and the drug can even be self-administered as eye drops.
The administration of NGF to the target areas of the brain via
the ophthalmic route is theoretically hindered by the molecular
weight of the active form of NGF (14.5 KDa) which does
not permit its passage through the cornea. However, NGF is
unexpectedly absorbed, albeit at a low concentration, reaching
the retina, optic nerve and finally the brain (Lambiase et al., 2005;
Di Fausto et al., 2007; Lambiase et al., 2007b) via different paths.
From the optical surface, several routes direct the transport of
the molecule to the posterior segment (Maurice, 2002; Koevary,
2005). NGF receptors are highly expressed throughout the visual
system (Wang et al., 2014), and its voyage starts by binding
the high affinity receptor TrkA in the anterior part of the eye
(Roberti et al., 2014).
Nerve growth factor appears to be transported mainly by
the trans-conjunctive/trans-sclera pathways, although systemic
absorption and passage through the retrobulbar space have also
been hypothesized (Maurice, 2002; Koevary et al., 2003).
Following the passage from the anterior to the posterior part
of the eye, the cells in the retina and the RGCs transport NGF
along their axons via anterograde or retrograde mechanisms
(Carmignoto et al., 1991), indeed anterograde transport and
systemic absorption may explain the increased levels of the
molecule in the contralateral eye. NGF eye drops also induce
c-Fos in the neurons of the primary visual areas of the
CNS, supraoptic and paraventricular nuclei, hippocampus,
frontal cortex and amygdala, indicating that all the retinal
pathways are activated and that NGF also acts through post-
synaptic modulation of cells localized in different brain areas
which receive the retinal signals, either directly or indirectly
(Tirassa et al., 2018).
An animal study on rats using radiolabeled NGF
demonstrated that following eye drop administration, the
molecule is present in the conjunctiva, sclera, choroid, retina
and optic nerve. In the retina and the optic nerve, NGF was
detected as early as 2 h after administration, reaching maximum
level at 6 h and disappearing from the eye tissues after 48 h
(Lambiase et al., 2005).
Ocular and intranasal application, with their ease of delivery,
offer attractive alternatives to the systemic delivery of NGF,
bypassing the BBB (Frey et al., 1997; Thorne and Frey, 2001; Aloe
et al., 2014). A drawback is the low delivery efficiency. Moreover,
the specificity of the treatment is uncertain and highly variable,
with unpredictable, albeit minimal systemic effects.
Skin
Topical NGF applications also include the skin, where it acts
locally and is highly effective in wound healing promotion. The
cellular actors involved in epithelial tissue repair (keratinocytes,
dermal fibroblasts, and myofibroblasts) are cells which produce
or respond to NGF, expressing the TrkA high-affinity receptor
(Palazzo et al., 2012; Matsumura et al., 2015; Samarasena et al.,
2015). In this context, NGF also exerts an angiogenic action on
endothelial cells (Calzà et al., 2001; Nico et al., 2008), a direct
action on inflammatory and immune cells (Minnone et al., 2017),
and a direct effect on the thinly myelinated Aδ- or unmyelinated
C-fibers that innervate the dermis and epidermis (Indo, 2010).
This is also demonstrated by the role of endogenous NGF in
skin and mucosal wound healing in various animal models and
human pathologies (Levi-Montalcini, 1987; Chéret et al., 2013).
Taking this evidence as a starting point, several reports have
described the positive effect of NGF in epithelial wound healing,
including chronic non-healing cutaneous ulcers in diabetic
rodent models, where a defect of endogenous NGF is supposed
(Tiaka et al., 2011). Our group demonstrated in vitro that NGF
action is directed at the main cell types involved in wound
healing (keratinocytes, fibroblasts, and endothelial cells), as well
as at hyperglycemic conditions which mimic the pathological
microenvironment of diabetes (Gostynska et al., 2019). We
also tested the efficacy of a non-algogenic NGF derivative
(hNGFP61S/R100E), named CHF6467 (Chiesi Farmaceutici).
This molecule is a rhNGF containing an amino acid substitution,
which removed the NGF-related hyperalgesic effect, while
maintaining its ability to induce wound healing. CHF6467
treatments of pressure ulcers in diabetic mice accelerated
skin repair, increasing re-epithelization, re-innervation, and re-
vascularization (Giuliani et al., 2020). Our results confirmed
other studies (Muangman et al., 2004), with the remarkable
difference that we used a non-algogenic rhNGF, thus potentially
overcoming the main limitation to the clinical application of NGF
(Giuliani et al., 2020).
Besides its role in angiogenesis (Calzà et al., 2001; Ahluwalia
et al., 2017; Li X. et al., 2018) and its action on skin cells
(Gostynska et al., 2020), NGF may act by improving local re-
innervation, fundamental to the wound healing process (Kiya and
Kubo, 2019). Our transcriptomic study on the CHF6467 molecule
also points to the modulation of Akt/mTOR signaling as the main
driver of NGF action (Giuliani et al., 2020). This pathway is
in fact in involved in the wound healing process (Huang et al.,
2015; Jere et al., 2019) and is regarded as a therapeutic target
(Squarize et al., 2010).
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FIGURE 2 | NGF and the visual system. (A) Horizontal cross section of the brain, showing the optic nerves originating from retina and crossing at the optic chiasm.
Each optic tract travels to its corresponding cerebral hemisphere to reach the lateral geniculate nucleus in the thalamus and to the contralateral hemisphere to reach
the primary visual cortex. (B) Horizontal cross section of the eye showing the anterior (cornea, conjunctiva, iris, ciliary body, and lens) and a posterior (sclera, choroid,
retina, and optic nerve) ocular segment, filled with the vitreous fluid. From the retina, the retinal ganglion cells axons form the nerve fibers converging in the optic disk
and forming the optic nerve. (C) NGF, TrkA, and p75NTR expression in the different cellular populations of the retina (data from Garcia et al., 2017).
BIOMATERIAL-ASSISTED DELIVERY
Biomaterial-based systems (nanomedicine, hydrogels and
scaffolds) are a common strategy to ameliorate drug delivery,
and enormous advances have been made over the last decades
to assist tissue repair and regeneration by biomaterial loading
different growth factors (GF) (Lee et al., 2011). The use of
biomaterials has been proposed to support macromolecule
topical application and to facilitate the body’s barriers crossing.
For example, nanotherapeutics and nanomaterials improve the
biodistribution of drugs throughout the brain for more effective
treatments, not only via convection-enhanced delivery, but also
via IN delivery (Keller et al., 2021).
But in spite of this progresses at the material side in controlling
hydrophobicity/hydrophilicity, micro/nano-architectures,
porosity, stiffness, and degradation rate, translation of materials
to clinical applications is still limited due to difficulties such
as scaling up reproducible manufacturing processes, the low
stability of encapsulated proteins and their rapid inactivation by
enzymes under physiological conditions.
Hydrogels for NGF Delivery
Hydrogels are polymers with a 3D network and a hydrophilic
structure with the potential to absorb up to thousands of
times their dry weight in water (Hoffman, 2002). Their unique
properties, including gelation time and gelation temperature,
mechanical strength, degradability together with their good
affinity and compatibility with biological tissues, make hydrogels
versatile materials for drug delivery and scaffolding for tissue
engineering applications (Naahidi et al., 2017). The use of
hydrogels as carrier materials for NGF is an important
strategy to protect this protein from inactivation, ensure its
sustained delivery over time, and improve its regenerative effects.
Conventional hydrogels may be unsuited to wrapping NGF
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due to a poor affinity to NGF, or to the lack of particular
requirements such as a certain mechanical strength or shape
at normal body temperature, and thermo-sensitive hydrogels
may offer a valid alternative. These polymers are liquid at
room temperature, changing into a 3D-network structure at
normal body temperature, thus rapidly transforming from a
solution to a viscoelastic gel making them particularly suitable for
in vivo application.
Polysaccharide-Based-Hydrogels
Heparin poloxamer (HP) is a thermo-sensitive hydrogel with
good affinity to NGF (Zhao et al., 2016). NGF-HP hydrogel
maintains its thermosensitive nature and has a porous sponge-
like structure which is ideal for carrying NGF and controlling
its release. In an in vivo study on spinal cord injury (SCI)
rat model, the NGF-HP hydrogel by in situ injection reduced
the formation of a glial scar by inhibiting the generation of
reactive astrocytes following SCI, promoting axon regeneration
and inhibiting the formation of proteoglycans and collagen fibers,
as well as promoting the formation of the new blood capillaries
required for regeneration process. Moreover, and improvement
in the locomotion performance was also observed.
Controlled delivery of multiple GFs to lesion areas is becoming
an attractive strategy to achieve successful axonal regrowth
following SCI. The HP hydrogel was therefore used for the
delivery of both NGF and fibroblast growth factors (bFGF) (Hu
et al., 2020). The release of these GFs from the hydrogel exhibited
an initial rapid phase during the first week, and a slow sustained
release. The GF-HP hydrogel was also used in a diabetic rat model
with sciatic nerve crush injury to enhance the peripheral nerve
regeneration with a single injection of GF-HP hydrogel. After
30 days, the GFs attenuated gastrocnemius muscle atrophy, and
promoted the formation of myelinated axons, the proliferation of
Schwann cells, and motor function recovery. However, the study
lacks electrophysiology data and control experiments by single
growth factor administration (Li R. et al., 2018).
Hydrogels carrying bioactive molecules can be used as
cavity fillers in nerve conduits (NCs) for nerve reconstruction,
in order to provide an ideal microenvironment for axonal
regeneration. To promote the regeneration of a 5 mm gap
in a rat facial nerve, an autologous vein was filled in situ
with a thermosensitive Chitosan/β-glycerophosphate hydrogel
loading NGF. While good functional recovery was achieved, the
performance of the hydrogel was inferior to autologous nerve
grafting (Cao et al., 2012). Alternatively, an electrospun conduit
composed of aligned poly-L-Lactide-co-caprolactone (PCLC)
nanofibers was filled with an NGF-loaded collagen/hyaluronan
hydrogel (Jin et al., 2013). This NGF/PCLC/Hydrogel system
enhanced neurite outgrowth from cultured dorsal root ganglia
explants, compared to the plain PCLC/hydrogel. This result was
not replicated in vivo to repair 10 mm gap in rat sciatic nerve,
where no statistical difference in motor functional recovery and
histomorphology were observed.
The combination of NGF with scaffolds presenting an ordered
microstructure has also been employed (Singh et al., 2018). For
example, an aligned open pore structure was generated inside a
3D printed conduit by directional cryogelation of a chitosan and
gelatin solution, followed by physical absorption of NGF on the
dried scaffold. When used in grafting a 15 mm gap in a rat sciatic
nerve, these NCs showed significantly better results compared
to the random scaffold, and even matched the performance
of the autograft.
To treat chronically compressed nerves, a chitosan and sericin
(CS-SS) scaffold cross-linked with genipin was developed for
NGF delivery (Zhang et al., 2017). The round flake-like scaffolds
were folded and adhered to the injured nerve after decompression
in the in vivo rat model. The number and thickness of myelinated
nerve fibers and axons increased, and atrophy and function
impairment of the gastrocnemius muscle was suppressed.
Another scaffold-based strategy using hydrogels is aimed to
obtain NGF concentration gradients, thus supporting axonal
regeneration by adapting NGF release to the stage of the repair
process. The use of such gradients in vivo to repair a challenging
20 mm gap in rat sciatic nerve was recently reported (Dodla and
Bellamkonda, 2008). A polysulphone nerve guidance channel was
filled with agarose hydrogel containing gradients of NGF and/or
laminin, and nerve regeneration was evaluated in comparison
with an autograft implant and an isotropic scaffold, containing
a homogenous distribution of NGF and laminin. The anisotropic
hydrogel with a concentration gradient in both NGF and laminin
was the only one leading to an improved axonal regeneration,
suggesting a synergistic effect, although the nerve autograft gave
again the best results.
The ability of NGF to trigger the survival and neuronal
differentiation of human adipose-derived stem cells (hADSCs)
was exploited in the treatment of erectile disfunction in
a rat model caused by an injury of the cavernous nerve.
A biocompatible and biodegradable hydrogel composed of
hyaluronic acid and polyethylene oxide was used as a delivery
vehicle for both NGF and hADSCs by a single injection at the
injury site. The hydrogel guaranteed a continuous release of NGF
in vitro and led to an improved regeneration of the cavernous
nerve, leading to a recovery of erectile function (Kim et al., 2013).
Other approaches have been used to exploit the biological
effect of NGF without using the isolated protein itself, such as
the use of NGF-overexpressing genetically modified hADSCs,
which has been for example incorporated into a thermosensitive
chitosan β-glycerophosphate/hydroxyethyl cellulose hydrogel to
treat a spinal cord contusion in rats (Alizadeh et al., 2020).
Protein- and Peptide-Based-Hydrogels
The thermo-responsive hydrogel consisting of methoxy-poly
(ethylene glycol)-b-poly(γ-ethyl-L-glutamate) (mPEG-PELG)
was also successfully used to load NGF and obtain a controlled
release (Liu et al., 2019). In a rat model, a 10 mm segment of
sciatic nerve was dissected and removed, and the gap bridged
using a chitosan conduit with the lumen filled of NGF/mPEG-
PELG. The morphological, electrophysiological and functional
analyses revealed that the chitosan scaffold with NGF/mPEG-
PELG achieved superior regenerative outcomes compared to
plain scaffolds or to a daily intramuscular injection of NGF.
Microporous hydrogels are another useful material. GelMA
is a photo-crosslinking hydrogel composed of modified collagen
components which retains cell adhesive peptide (arginyl-glycyl
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aspartic acid, RGD) as well as matrix metalloprotease peptides
(MMP). The GelMA hydrogel was used to create an adaptable
microporous hydrogel (AMH), facilitating the formation of a
stable 3D porous scaffold (Hsu et al., 2019). The adaptable
microporous scaffold has cell-penetrable pore sizes and was
integrated with a propagating gradient of NGF in a NC.
The GelMA hydrogel loaded with NGF (NGF-G-AMH@) was
implanted into the 5 mm transected sciatic nerve in SD mice.
NGF-G-AMH@ directed axon outgrowth of up to 4.7 mm
in 4 days in vivo, with well aligned axons and functional
recovery within 30 days post-surgery. A gel material composed of
collagen, nanohydroxyapatite and carrageenan (Col/nHA/Carr)
closely mimics natural bone composition and microstructure,
and provides a sustained release of human NGF-A upon
loading (Wang et al., 2009). In a rabbit model of mandible
distraction osteogenesis (DO), a single injection of NGF-A in a
Col/nHA/Carr gel at the end of a distraction period enhanced
histological and morphometric nerve parameters. A more rapid
recovery from the inferior alveolar nerve injury was observed
due to a sustained release of NGF from the gel, which continued
to exert its biological activity for a prolonged period. However,
neurophysiological and behavioral studies are needed to test
the effects of the locally applied NGF/Col/nHA/Carr gel on
neurosensory functions (Wang et al., 2010).
The Col/nHA/NGF construct also accelerated bone formation
in the same model. Although in vitro release studies were
not conducted, the authors hypothesized that the hydrogel
system prevents biodegradation of the NGF and guarantees a
sustained release in vivo, which, combined with the intrinsic
osteoconductive action of COL/nHA, led to an improvement in
bone regeneration (Chao et al., 2016).
Nerve growth factor concentration gradients have been
recently achieved using a modified 3D printer apparatus to get a
continuous NGF concentration gradient in a silk fibroin/collagen
hydrogel then subjected to directional freezing to finally
obtain a 3D scaffold displaying both biochemical gradient and
longitudinally oriented microchannels. It was demonstrated that
both the NGF gradient and the oriented structure synergistically
promoted nerve regeneration on a 15 mm gap in rat sciatic nerve
in vivo, accelerating functional recovery, but these results were
not compared to an autograft nerve repair (Huang et al., 2020).
Amphiphilic diblock co-polypeptide hydrogels (DCH) using
poly-leucine and poly-glutamate or poly-lysine can be deformed
and thinnered by stress, thus injected through small-bore
cannula, after which they self-assemble into rigid gel networks
that degrades in about 56 days. NGF could be loaded in DCH
which mediate its sustained release in vivo inside the BBB of the
CNS (Song et al., 2012). When injected in the basal forebrain,
depots of DCH-NGF provided a more prolonged delivery of
NGF compared with NGF injected in buffer, which induced
and maintained the hypertrophy of local forebrain cholinergic
neurons for at least 28 days. This hypertrophic reaction of
neurons seems to follow a gradient effect from the depot, and
being more evident close and attenuate far from the depot.
Nerve growth factor loaded in a gelatin-polyethylene glycol-
tyramine hydrogel together with bFGF loaded in heparin-
pluronic nanogels and PCL beads as a passive bulking agent was
tested to treat stress urinal incontinence (SUI). The combined
action of NGF and bFGF, which were released at different
rates, led to a significant improvement in regeneration and
reinnervation of the damaged smooth muscle around the urethra
in a rat model of SUI (Oh et al., 2015).
Finally, NGF and BDNF with mimicking peptides were used
to functionalize RADA16-1, a self-assembling peptide capable
of forming nanofibrous hydrogels under certain conditions (Lu
et al., 2018). The hydrogel was used to fill a chitosan NC to graft
a 10 mm gap in rat sciatic nerve.
Nanofibrous Electrospun Scaffolds for
NGF Delivery
Among the more useful processing strategies to fabricate
nanofibers, electrospinning is one of the best known methods
(Greiner and Wendorff, 2007). Electrospun nanofibers with a
defined micro/nanoarchitecture in terms of fiber size (fiber
diameters range from a few hundreds of nanometers to tens of
micrometers) and fiber orientation, have been used as a scaffold
for a wide range of tissue engineering applications including
neural, cardiovascular, bone and skin tissue engineering.
Nanofibrous electrospun scaffolds offer a promising alternative
to autologous grafting in peripheral nerve injuries, and have
been extensively studied for neural tissue repair and regeneration
(Ghane et al., 2021), due to their ability to act both as matrices
for cells and as a delivery vehicle for various biomolecules such
as NGF and glial cell line-derived neurotrophic factor (GDNF)
(Liu et al., 2018; Bighinati et al., 2020). There are several reasons
for the great interest in electrospun constructs in neural tissue
engineering: ease of manufacture, production using a variety of
natural and synthetic polymers, structural similarity with the
extracellular matrix, and tunable morphology and mechanical
properties. Of their various advantages, the ease of nanofiber
functionalization is perhaps the most relevant, since biomolecules
and drugs can easily be incorporated into electrospun scaffolds
by means of several methods, including physical adsorption,
blend electrospinning, coaxial electrospinning, and covalent
immobilization. The nanometer scale of the fibers provides
an extremely high surface-to-volume ratio, and contributes to
improving biological functionality and biomolecule delivery (Ji
et al., 2011). To tackle the problems related to the possible
destabilization and denaturation of biomolecules such as growth
factors when exposed to organic solvents in a traditional
electrospinning process, variations in the technique, such as
coaxial or emulsion electrospinning, have been employed to
preserve the bioactivity of the incorporated biomolecules, thus
enhancing the efficiency of incorporation, while controlling the
release kinetics of the biomolecules at the same time.
A variety of natural and synthetic materials have been used to
manufacture aligned structures for nerve regeneration, however
only a few studies report significant results on the biomaterial-
assisted delivery of NGF for in vivo applications.
In a detailed study recently published by Zhu et al. (2020)
highly aligned poly(ε-caprolactone) (PCL) fibers with NGF
gradients were developed for peripheral nerve regeneration. NGF
was incorporated into the conduit following its manufacture,
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preventing the biomolecule from being negatively affected by the
organic solvents used during the electrospinning process. In vitro
studies demonstrated that the conduits enhanced and attracted
the longitudinal neurite growth of the dorsal root ganglion
(DRG) neurons toward their high-concentration gradient side.
In vivo, the conduits directed a stronger longitudinal attraction
of axons and migration of Schwann cells in 15 mm rat sciatic
nerve defects. At 12 weeks, rats transplanted with the conduits
showed satisfactory morphological and functional improvements
in g-ratio and total number and area of myelinated nerve
fibers, as well as sciatic function index, compound muscle action
potentials, and muscle wet weight ratio, as compared to aligned
conduits with uniform NGF distribution. mRNA-seq and RT-
PCR results also revealed that Rap1, MAPK, and cell adhesion
molecule signaling pathways were closely associated with axon
chemotactic response and attraction. The performance of the
NGF-gradient aligned conduits was similar to that of autografts,
demonstrating the great potential of the proposed scaffolds in
repairing peripheral nerve defects.
More commonly, NGF is incorporated homogeneously into
the nanofibers by means of coaxial or emulsion electrospinning.
In the study by Kuihua et al. (2014), an artificial nerve
guidance conduit for nerve gap regeneration was designed
and manufactured via coaxial electrospinning. Aligned core-
shell nanofibers were obtained, with the shell made of a silk
fibroin/poly(lactic-acid-co-caprolactone) blend [SF/P(LLACL)],
and the core consisting of SF encapsulating NGF. This approach
permitted stabilization of the NGF during the electrospinning
process, and contributed to a controlled sustained release of NGF.
A sustained release of biologically active NGF was observed,
using ELISA and a PC12 cell-based bioassay, over a 60-day
time period, although the number of neurons was lower than
the positive control. The core-shell fibrous conduits were then
used as a bridge implanted across a 15-mm defect in the sciatic
nerve of rats. The outcome in terms of regenerated nerve at
12 weeks was evaluated by a combination of electrophysiological
assessment, histochemistry, and electron microscopy, and the
results, taken together, demonstrated that the NGF-aligned fibers
promoted peripheral nerve regeneration significantly better than
the same conduit without NGF, suggesting that the released NGF
may effectively promote the regeneration of peripheral nerves. In
an analogous study, very similar random core-shell nanofibers
were prepared by coaxial electrospinning, consisting of a shell
of P(LLA-CL) and a core of BSA/NGF (Liu et al., 2011), and
the conduits used for sciatic nerve regeneration in rats. The
functional and histological analyses revealed that the parameters
related to the number and arrangement of regenerated nerve
fibers, myelination, and nerve function reconstruction for the
P(LLA-CL)/NGF group were similar to those obtained for the
group where the autograph nerve was implanted, and were
significantly better than for the group in which plain P(LLA-CL)
electrospun fibers were implanted, even in the presence of an
injection of NGF solution.
In the study by Zhang et al. (2015), a composite micro/nano-
fibrous scaffold with core–shell structure was manufactured
by coaxial electrospinning, combining synthetic polymers
(polypyrrole, PPy) as a conductive polymer and poly(L-lactic
acid, PLLA) with natural polymer and biomolecules (spider
silk protein, Lysine and NGF). In vitro tests revealed that the
scaffold was able maintain a stable structure for at least 4 months
in buffered solution, with a degradation rate comparable to
the nerve growth rate. Good biocompatibility and good cell
adhesion with PC 12 cells were demonstrated. In vivo evaluation
also showed that the composite fibrous conduit was effective
at bridging a 20 mm sciatic nerve gap in adult rats within
10 months, and electrical stimulation through the conduit
promoted Schwann cell migration and axonal regrowth.
In addition to coaxial electrospinning, emulsion
electrospinning can be also used to incorporate biomolecules
while preserving their bioactivity, a method used to load
recombinant human NGF into the core of emulsion electrospun
PLLA nanofibers (Xia and Lv, 2018). The resulting nanofibrous
scaffold was then additionally loaded with recombinant human
vascular endothelial growth factor (VEGF) on the surface to
achieve a controlled dual-delivery of the biomolecules. In vitro
studies showed a sequential release pattern of VEGF and NGF,
with most of the VEFG released in the first few days, whereas
the NGF loaded in the fiber core was continuously released
for more than 1 month. After demonstrating that the scaffold
enhanced neural differentiation of iPSC-NCSC cells in vitro,
it was implanted into a critical-size defect in a rat sciatic
nerve model. Footprint analysis, electrophysiological tests, and
histological analysis revealed a significant improvement in
neovascularization and nerve healing 3 months after surgery.
The potential of electrospinning to prepare an aligned
fiber matrix able to influence the directionality and growth
of axons in the CNS was investigated in the study by
Colello et al. (2016). A composite material was prepared
by electrospinning polydioxanone (PDO) in the presence of
alginate beads incorporating NGF and chondroitinase ABC
(ChABC). Upon implantation in a completely transected rat
spinal cord, the composite matrices supplemented with NGF and
(ChABC) promoted significant functional recovery. Examination
of the conduits post-implantation revealed that electrospun
aligned fibers induced a more robust cellular infiltration than
random fibers. A vascular network was also generated in these
matrices, since electrospun fibers acted as a growth substrate for
endothelial cells. The presence of axons within the implanted
electrospun matrix demonstrated that the aligned composite
fibers containing NGF are able to provide trophic support
and directional guidance cues to regenerating axons following
spinal cord injury.
In a very recent and exhaustive study, emulsion
electrospinning was used to develop innovative
microenvironment-responsive (pH-responsive)
immunoregulatory electrospun fibers to promote nerve function
(Xi et al., 2020). PLLA-based scaffolds were manufactured,
containing Rat-β-NGF microsol particles wrapped in the core of
the fiber during the electrospinning process from a homogeneous
and stable water-in-oil emulsion. IL-4 plasmid-loaded liposomes
(pDNA) were then grafted onto the surface of the electrospun
fiber scaffolds. The resulting biomimetic scaffold responded
directly to the acidic microenvironment at focal areas, followed
by triggered release of the IL-4 plasmid-loaded liposomes within
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a few hours to suppress the release of inflammatory cytokines and
promote the neural differentiation of mesenchymal stem cells
in vitro. A Sprague Dawley (SD) rat spinal hemisection model
was used to investigate the in vivo performance on inflammation
suppression, nerve regeneration and functional recovery.
Once implanted into the rats with acute spinal cord injury,
the scaffold showed sustained NGF release, achieved by the
core-shell structure, and brought a significantly shifted immune
subtype to down-regulate the acute inflammation response,
reduce scar tissue formation, promote angiogenesis and neural
differentiation at the injury site, and enhance functional recovery
in vivo.
Overall, electrospinning-based technologies allow an
extraordinary range of manufacturing opportunities for finely
tuned design suitable for topical application. Moreover, several
studies have also demonstrated that NGF bioactivity is not
compromised by the electrospinning processing, making this
technology suitable for applications in dermatology, but also
neurosurgery and orthopedics.
Nanomedicines for NGF Delivery
While biomacromolecules offer promising and possibly
fundamental pharmaceutical treatments for controlling and
tacking diseases, their action is hampered by severe limitations
in delivery. This is due to chemical and physical instabilities, as
well as difficulties in crossing physiological barriers, and to being
accumulated and released over time at the correct site of action
(Duskey et al., 2017; Tosi et al., 2019).
Conventional drug delivery strategies cannot address these
limitations leading to the increase in the number of polymeric or
lipidic nanomedicine (NMed) applications which have incredible
potential for the medical field (Germain et al., 2020) to: (i)
stabilization of the biomacromolecules by encapsulation within
a polymeric or lipidic matrix, therefore assuring the required
level of protection of biological activity, and (ii) a controlled
release of pharmacologically relevant amounts of therapeutics at
the site of action.
Depending on the material used, NMeds can be tuned
in terms of size, shape, charge, binding capacity and
hydrophobicity/hydrophilicity, and are easily scaled-up in
view of future production on an industrial scale. This allows
for a quality by design approach of an NMed with tunable
characteristics to be compatible with (i) the drug characteristics;
(ii) the required drug release profiles, and (iii) the characteristic
or biological/pathological environment in order to control the
pharmacokinetic half-life, biodistribution, stability, and overall
therapeutic activity of the loaded macromolecule to be managed
and regulated ad hoc.
One example, NGF is the most potent growth stimulating
factor for cholinergic neurons and has been shown to prevent the
degeneration of dopaminergic neurons, making it a promising
candidate for the treatment of neurodegenerative diseases such as
Alzheimer’s and Parkinson’s disease (Kurakhmaeva et al., 2008,
2009). Regarding NGF delivery by means of nanomedicines,
several attempts have been made to improve loading and
delivery across the BBB by engineering various polymers with
different BBB targeting ligands. One example was the use of a
poly(alkyl-cyanoacrylate) polymer coated with polysorbate 80 to
promote BBB crossing (Kurakhmaeva et al., 2008, 2009). This
coating promoted the adsorption of apolipoproteins onto the
nanoparticle (NPs) surface, and the contact of the NPs with the
brain capillary endothelial cells which promoted endocytosis and
the intracellular release of the drug.
In the same study, NGF was adsorbed on the surface of
polybutylcyanoacrylate (PBCA) NPs coated with polysorbate-80
(PS-80) surfactant for antiparkinsonian effects (Kurakhmaeva
et al., 2008). Pre-treatment of the mice with NGF-loaded NPs
coated with PS-80 15 min before MPTP (used to provoke
parkinsonian syndrome) showed a considerable decrease in
parkinsonian symptoms such as a 37% decrease in latero- and
retropulsion and a 34% decrease in catalepsy as early as day 1 of
observation when compared to control groups.
It is noteworthy that the total index of vertical and horizontal
motor activity in the group receiving NGF-loaded NPs coated
with PS-80 after MPTP was 1.78-fold higher compare to control,
while treatment before MPTP induction was 2.86 times higher
suggesting a potential protective effect. The effects of NGF-loaded
NPs persisted for 7 and 21 days following a single injection
of the neurotoxin proving to be one of the most promising
NMed carriers by preventing the scavenging of the NGF by the
cells of the reticuloendothelial system, prolonging circulation of
these particles in the blood and increasing their concentration in
cerebral vessels.
Similar experiments were conducted to explore the effect of
NGF adsorbed on PBCA NPs coated with polysorbate-80 in
Alzheimer’s disease. Acute amnesia in mice was induced by
subcutaneous injection of scopolamine before training in the
step-through passive avoidance reflex (PAR) test to determine
effects on memory (Kurakhmaeva et al., 2009). The NGF-loaded
PBCA NP formulation produced significantly increased latent
periods in the passive-avoidance reflex (PAR) test, compared
to the control animals who only received scopolamine. In
contrast, systemic administration of the NGF in solution did
not induce any significant changes in the mental or cognitive
activity of the animals after induction of these changes by
scopolamine pretreatment.
Nerve growth factor was also encapsulated into a chemically
crosslinked albumin nanocarrier matrix (HSA) with ultrasmall
particles of iron oxide surface-modified with apolipoprotein E
to facilitate active transport into the brain and allow it to be
used as a theranostic agent (Feczkó et al., 2019). The HSA
NPs exhibited a size of 212 ± 1 nm, a polydispersity index
(PDI) of 0.075 ± 0.022 and a zeta potential of -48.3 mV. The
biocompatibility of these nanocarriers and the bioactivity of
NGF were confirmed in rat pheochromocytoma (PC12) cells.
Following modification of the particle surface with Apo E, the
particles were able to cross the BBB and remained bioactive in
terms of neurite outgrowth regulation.
In addition to Apo E, Apolipoprotein A-I was used to coat
NGF lipoprotein (HDL)-mimicking NPs (Zhu and Dong, 2017).
High-density lipoprotein (HDL)-mimicking NPs is a natural
NP consisting of a lipid core coated with apolipoproteins,
and a phospholipid monolayer which plays a critical role in
the transport of lipids, proteins, and nucleic acids via its
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interaction with target receptors. The HDL-mimicking NPs
successfully encapsulated NGF, resulting in a long half-life,
prolonged release (10% over 72 h), in vivo stability, and increased
physiological effects.
In another approach (Song et al., 2017), non-viral poly(lactic-
co-glycolic acid) (PLGA) nanobubble (NBs) vectors, possessing
unique advantages such as targeting, slow release and
penetration, were used as gene carriers to deliver NGF. PLGA
is one of the most successful polymers used in the development
of drug delivery systems, offering excellent biocompatibility and
biodegradability of NPs (Tan et al., 2013; Ruozi et al., 2015).
The NGF/PLGA NBs formed by double emulsion was
215.3 ± 55.29 nm, the PDI was 0.027 and the zeta potential
was –11.3 ± 5.65 mV. It underwent Ultrasound (US)-mediated
destruction to deliver NGF, resulting in diminished histological
injury, neuron loss and neuronal apoptosis, and increased BBB
scores in a rat model of spinal cord injury.
Chitosan, another widely used biodegradable and
biocompatible polymer was used by Razavi et al. (2019) to
encapsulate NGF in chitosan nanoparticles (NGF-CNPs). NGF-
CNPs were characterized by photon-correlation spectroscopy
analysis, which showed a mean NGF-CSNP diameter of
147.04 ± 8.09 nm, and a good stability of the nanoparticle
surface charge (36.47 ± 1.88 mV). The encapsulation efficiency
of NGF in chitosan nanoparticles is 83.93 ± 2.45%. These
NMeds were evaluated for their differentiation potential of
human adipose-derived stem cells (h-ADSCs) to Schwann-like
cells as a source for treating various diseases such as peripheral
nerve regeneration multiple sclerosis and diabetic neuropathy
(Razavi et al., 2019). NGF-CNPs demonstrated no cytotoxicity
and offered a sustained release of NGF reaching 74.63 ± 2.07%
over 7 days without any initial burst release leading to an
increased differentiation of h-ADSCs into Schwann-like cells and
myelinating capacity in vitro.
Similarly, NGF was encapsulated into NPs [n(NGF)] of
methacryloyloxyethyl phosphorylcholine (MPC), analogous to
choline and acetylcholine, and polylactic acid (PLA) diacrylate
to provide proof of CNS targeting in healthy mice following
intravenous injection (Xu et al., 2019). The MPC-PLA exhibited
an average diameter of 30.3 ± 3.6 nm under TEM, and a zeta
potential of 24 mV. PC12 cells were treated with native NGF
and NGF NPs to assess the activity of the NGF released from
the nanocapsules. When the NGF was released from the NPs,
it induced the differentiation and neurite outgrowth of these
cells through intracellular pathways. The therapeutic benefit of
n(NGF) for CNS repair following injury was evaluated in a
mouse model of compression-induced acute spinal cord injury.
After 21 days, extensive ankle movements and occasional plantar
stepping was observed, representing a significant functional
recovery in locomotion.
Besides these results, widely reviewed in the past literature
(Ruozi et al., 2012; Srikanth and Kessler, 2012; Angelova et al.,
2013; Géral et al., 2013), we would like to highlight some key
factors which may significantly improve the chances of success
for NMed in the field of biomacromolecule delivery.
Regarding the choice of NMed, its design and production,
a major concern, still hotly debated, regards two main aspects
of nanoproduction. The first is the absolute conviction that it
is possible to develop one single nanomedicine for every drug
(or macromolecule), the so-called “magic bullet” (Strebhardt and
Ullrich, 2008; Flühmann et al., 2019), is neither more a reality
nor the future. This erroneous view of the magic bullet led to
many years of research without any real or concrete advances in
the translatability of NMeds to a clinical setting. Therefore, it is
pivotal, when approaching a NMed design to consider the future
NMed as a single product together with the embedded drug.
The second aspect, especially when considering
biomacromolecules such as NGF, proteins or enzymes,
relates to the stability of the biological drugs throughout
the preparation procedure and during storage. The greatest
drawback concerns the requirements of nanoproduction (such
as stirring, heating, sonication, organic solvents, etc.), which
severely impact the stability and maintenance of the biological
drug’s pharmacological activity (Duskey et al., 2020). Some
of these requirements relate to the polymer/lipid used in the
formulation, and should be carefully designed and always
adapted to the “stability features” of the embedded drug.
Failure to take these aspects into consideration when designing
the NMed risks rendering the loaded drug ineffective, thus
defeating its purpose.
GENE THERAPY AND CELL-ASSISTED
BIODELIVERY
Nerve growth factor cell and gene therapy for the CNS,
in particular to target cholinergic degeneration in AD, has
been investigated in preclinical models and also tested in
human studies (Hosseini et al., 2018; Mitra et al., 2019),
particularly in the United States (Rafii et al., 2018) and Sweden
(Eyjolfsdottir et al., 2016).
Results from the US study on gene therapy in AD patients
have recently been reviewed to include CNS analysis following
autopsy. Intraparenchymal adeno-associated virus serotype 2
(AAV2)-NGF delivery was safe but did not improve cognition.
Neuropathological analysis then aimed to establish whether
(AAV2)-NGF engaged the target cholinergic neurons of the basal
forebrain. Patients with clinically diagnosed early- to middle-
stage AD received a total dose of 2 × 1011 vector genomes
of AAV2-NGF by stereotactic injection of the nucleus basalis
of Meynert. Following a mean survival of 4.0 years, AAV2-
NGF targeting, spread, and expression indicated that NGF gene
expression persisted for at least 7 years at the sites of AAV2-NGF
injection. However, the mean distance of AAV2-NGF spread was
only 0.96 ± 0.34 mm, indicating that NGF did not directly reach
the cholinergic neurons at any of the 15 injection sites. Given
that AAV2-NGF did not directly engage the target cholinergic
neurons, the authors cannot conclude that growth factor gene
therapy is effective for AD (Castle et al., 2020).
In the Swedish study, biodelivery of NGF (NGF-ECB)
by encapsulated cell was used in AD patients in a first-in-
human study. Results were gathered from a third dose cohort
of patients with mild to moderate AD, receiving second-
generation NGF-ECB implants with improved NGF secretion, in
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an open-label, phase Ib dose escalation study with a 6-month
duration. Each patient underwent stereotactic implant surgery
with four NGF-ECB implants generated using the Sleeping
Beauty transposon gene expression technology targeted at the
cholinergic basal forebrain, resulting in production of about
10 ng NGF/device/day. The data derived from this patient cohort
demonstrate the safety and tolerability of sustained NGF release
by a second-generation NGF-ECB implant to the basal forebrain.
Moreover, the patients’ responses to the NGF-treatment indicated
that approximately half of the patients responded to the ECB-
NGF-treatment with increased cholinergic markers (e.g., ChAT
activity) in the CSF, correlating to improved cognition and brain
glucose metabolism (Karami et al., 2015), less brain atrophy
(Ferreira et al., 2015), and normalization of the EEG-pattern
(unpublished data).
DISCUSSION
The discovery of endogenous GF production of GFs during
adulthood as well as during development opened new
perspectives for mature CNS biology, moving away from
the dogma of prominent histologist Ramon y Cajal: "Once
development ended, the founts of growth and regeneration of the
axons and dendrites dried up irrevocably. In the adult centers,
the nerve paths are something fixed, ended, and immutable.
Everything may die, nothing may be regenerated. It is for the
science of the future to change, if possible, this harsh decree." We
are now in the science of the future, knowing that endogenous
regeneration may occur in the mature CNS, albeit to a limited
extent. NGF can now be produced using human recombinant
technologies, and molecules which can limit adverse side-
effects are available either as modified full-length proteins or
as TrkA short peptides analogs. However, we still need to better
understand that NGF-based therapies should be considered as
“hormonal” therapies rather than conventional pharmacological
therapies, in view of the endogenous production of NGF. We
also need to protect the molecule from protein degradation,
and promote the crossing of blood-tissue barriers, in order to
bring the appropriate molecule concentration to the appropriate
place for the appropriate time. The use of modern biomaterial
technologies is an essential strategy for rapidly achieving this
goal. Scaffolds obtained by different fabrication procedures, such
as hydrogels and composite materials are providing significant
indications about efficacy of NGF delivery in peripheral nerve,
but also in other tissues repairs, as bone, while nanoparticle
conjugation is regarded as a promising strategy also to overcome
physiological barriers.
However, in view of clinical translation, we also need to move
forward in preclinical research, which, at the present, provides
a puzzling and incomplete picture of biomaterial potentiality.
In particular, we need well-designed proof-of-concept studies
for both safety and efficacy, thus including appropriate control
groups and defined functional end-points in the efficacy studies,
and the Good Laboratory Practice standard for safety studies.
Because of this, a more stringent interdisciplinary collaboration
would be desirable, such as a more stringent editorial policy in
both biomaterial and biomedical journals.
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